Collegium Pharmaceutical CEO and leadership

Joe Ciaffoni was appointed President and Chief Executive Officer of Collegium Pharmaceutical in July 2018. Joe Ciaffoni joined Collegium Pharmaceutical in May 2017 as Executive Vice President and Chief Operating Officer. Prior to joining Collegium, he served as President, U.S. Branded Pharmaceuticals of Endo International plc. Before that, Joe Ciaffoni held various positions of increasing responsibility at Biogen, including Senior Vice President, Global Specialty Medicines Group, Senior Vice President, U.S. Commercial and Vice President, U.S. Neurology Field Operations and Marketing. Prior to joining Biogen, he was Executive Vice President and Chief Operating Officer of Shionogi Inc. and President of Shionogi Pharmaceuticals. Joe Ciaffoni also previously served as Vice President, Sales for Schering-Plough (now Merck) and held several commercial leadership roles at Sanofi-Synthelabo (now Sanofi) and Novartis. Joe Ciaffoni received a B.A. in Communications and an M.B.A. from Rutgers.

Colleen Tupper is an EVP & Chief Financial Officer at COLLEGIUM PHARMACEUTICAL, INC and is based in United States. She has worked as Director, Finance at Shire HGT; Senior Finance Dir:Global Research & Development at Shire; and Vice President, US Commercial Finance at Shire. Colleen attended Franklin Pierce between 1998 and 2001.

Scott Dreyer was appointed Executive Vice President and Chief Commercial Officer in July 2018. Scott Dreyer joined Collegium in January 2018 as Senior Vice President of Sales, Marketing, Commercial Capabilities and Training. He has over 25 years of commercial experience across sales, marketing, commercial operations and strategic planning, all within the biopharma industry. Most recently, Scott Dreyer was Senior Vice President, Marketing and Commercial Operations for The Medicines Company. Prior to joining The Medicines Company, he was Vice President and Chief Marketing Officer-US at Biogen. Prior to Biogen, Scott Dreyer held various commercial leadership positions of increasing responsibility at Merck & Co including Vice President-US Hospital and Oncology Sales and Commercial Operations, Vice President-US Primary Care Sales, Executive Director US Regional Marketing Leader – Neuroscience, Executive Director Customer Marketing and Solutions, Sr. Director of Strategic Planning and Director of Cardiovascular Marketing. Throughout his career, he has been involved in the commercialization of over 35 products across more than 15 therapeutic areas and launched over 20 products. Scott Dreyer received his B.S. degree in Biology from Messiah College in Grantham, PA.

Joe Ciaffoni was appointed President and Chief Executive Officer of Collegium Pharmaceutical in July 2018. Joe Ciaffoni joined Collegium Pharmaceutical in May 2017 as Executive Vice President and Chief Operating Officer. Prior to joining Collegium, he served as President, U.S. Branded Pharmaceuticals of Endo International plc. Before that, Joe Ciaffoni held various positions of increasing responsibility at Biogen, including Senior Vice President, Global Specialty Medicines Group, Senior Vice President, U.S. Commercial and Vice President, U.S. Neurology Field Operations and Marketing. Prior to joining Biogen, he was Executive Vice President and Chief Operating Officer of Shionogi Inc. and President of Shionogi Pharmaceuticals. Joe Ciaffoni also previously served as Vice President, Sales for Schering-Plough (now Merck) and held several commercial leadership roles at Sanofi-Synthelabo (now Sanofi) and Novartis. Joe Ciaffoni received a B.A. in Communications and an M.B.A. from Rutgers.